TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (Claimed): Preparation of (I) comprises providing substituted 5,8-bis(5-bromo-2-thienyl)-2,3-diphenyl-6,7-dihydroquinoxaline compounds of formula (A) and N,N-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (B) in the absence of oxygen, where a molar ratio of the compound (A) to the compound (B) is 1:2-2.4, adding the compounds (A) and (B) into an alkali solution, a catalyst and an organic solvent, then performing Suzuki coupling reaction at a temperature of 70-130 degrees C for 12-48 hours, stopping the coupling reaction, and separating and purifying the obtained product. Preferred Method: The separating and purifying step comprises extracting the solid product obtained in the Suzuki coupling reaction using methylene chloride, removing the combined organic phases and then drying over anhydrous magnesium sulfate, and filtering the product using petroleum ether and ethyl acetate in a volume ratio of 10:1 as an eluent. The Suzuki coupling reaction is carried out at a temperature of 90-120 degrees C for 24-36 hours. The separating and purifying step is carried out using a chromatography on silica gel column under vacuum. Preferred Components: The organic palladium is bis(triphenylphosphine)palladium(II) dichloride, tetrakis(triphenylphosphine)palladium(0), or tris(dibenzylideneacetone)dipalladium(0), where the molar ratio of the organic palladium to the compound (A) is 1:4-1:8. The catalyst is an organic palladium phosphine ligand and an organic mixture, where the molar ratio of phosphine ligand to the compound (A) is 1:20-1:100. The phosphine ligand includes tri(o-tolyl)phosphine and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl. The organic solvent is toluene, N,N-dimethylformamide, or tetrahydrofuran. The mole ratio of the electronic receptor material to the electronic donor material is 1:1-3:1. SPECIFIC COMPOUNDS - 5 Compounds (I) are specifically claimed, i.e. 4-(5-(8-(5-(4-(diphenylamino)phenyl)-2-thienyl)-2,3-bis(3-octoxyphenyl)-6,7-dihydroquinoxalin-5-yl)-2-thienyl)-N,N-diphenyl-aniline of formula (Ia), 4-(5-(8-(5-(4-(diphenylamino)phenyl)-2-thienyl)-2,3-bis(3-icosoxyphenyl)-6,7-dihydroquinoxalin-5-yl)-2-thienyl)-N,N-diphenyl-aniline, 4-(5-(8-(5-(4-(diphenylamino)phenyl)-2-thienyl)-2,3-bis(3-hexoxyphenyl)-6,7-dihydroquinoxalin-5-yl)-2-thienyl)-N,N-diphenyl-aniline, 4-(5-(8-(5-(4-(diphenylamino)phenyl)-2-thienyl)-2,3-bis(3-methoxyphenyl)-6,7-dihydroquinoxalin-5-yl)-2-thienyl)-N,N-diphenyl-aniline, and 4-(5-(8-(5-(4-(diphenylamino)phenyl)-2-thienyl)-2,3-bis(3-dodecoxyphenyl)-6,7-dihydroquinoxalin-5-yl)-2-thienyl)-N,N-diphenyl-aniline.